These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

1265 related articles for article (PubMed ID: 17430582)

  • 1. Prognostic significance of bcl-2 expression in stage III breast cancer patients who had received doxorubicin and cyclophosphamide followed by paclitaxel as adjuvant chemotherapy.
    Lee KH; Im SA; Oh DY; Lee SH; Chie EK; Han W; Kim DW; Kim TY; Park IA; Noh DY; Heo DS; Ha SW; Bang YJ
    BMC Cancer; 2007 Apr; 7():63. PubMed ID: 17430582
    [TBL] [Abstract][Full Text] [Related]  

  • 2. Sequential adjuvant therapy with doxorubicin/paclitaxel/cyclophosphamide for resectable breast cancer involving four or more axillary nodes.
    Hudis CA; Seidman AD; Baselga J; Raptis G; Lebwohl D; Gilewski T; Currie V; Moynahan ME; Sklarin N; Fennelly D
    Semin Oncol; 1995 Dec; 22(6 Suppl 15):18-23. PubMed ID: 8643965
    [TBL] [Abstract][Full Text] [Related]  

  • 3. Multivariate analysis of DNA ploidy, p53, c-erbB-2 proteins, EGFR, and steroid hormone receptors for prediction of poor short term prognosis in breast cancer.
    Eissa S; Khalifa A; el-Gharib A; Salah N; Mohamed MK
    Anticancer Res; 1997; 17(2B):1417-23. PubMed ID: 9137508
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Prognostic value of lymph node metastases after neoadjuvant chemotherapy for large-sized operable carcinoma of the breast.
    Botti C; Vici P; Lopez M; Scinto AF; Cognetti F; Cavaliere R
    J Am Coll Surg; 1995 Sep; 181(3):202-8. PubMed ID: 7670678
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Postoperative radiotherapy in high-risk premenopausal women with breast cancer who receive adjuvant chemotherapy. Danish Breast Cancer Cooperative Group 82b Trial.
    Overgaard M; Hansen PS; Overgaard J; Rose C; Andersson M; Bach F; Kjaer M; Gadeberg CC; Mouridsen HT; Jensen MB; Zedeler K
    N Engl J Med; 1997 Oct; 337(14):949-55. PubMed ID: 9395428
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Supraclavicular lymph node metastases (SLM) from breast cancer as only site of distant disease: has radiotherapy any role?
    Pergolizzi S; Settineri N; Russi EG; Maisano R; Adamo V; Santacáterina A; Raffaele L; Marchetti G; Mesiti M
    Anticancer Res; 1997; 17(3C):2303-8. PubMed ID: 9216706
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Multivariate analysis of DNA ploidy, p53, c-erbB-2 proteins, EGFR, and steroid hormone receptors for short-term prognosis in breast cancer.
    Eissa S; Khalifa A; el-Gharib A; Salah N; Mohamed MK
    Anticancer Res; 1997; 17(4B):3091-7. PubMed ID: 9329609
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Breast cancer response to adjuvant chemotherapy in correlation with erbB2 and p53 expression.
    Jacquemier J; Penault-Llorca F; Viens P; Houvenaeghel G; Hassoun J; Torrente M; Adélaïde J; Birnbaum D
    Anticancer Res; 1994; 14(6B):2773-8. PubMed ID: 7872717
    [TBL] [Abstract][Full Text] [Related]  

  • 9. The prognostic significance of p53 and bcl-2 expression in lung adenocarcinoma and its correlation with Ki-67 growth fraction.
    Ishida H; Irie K; Itoh T; Furukawa T; Tokunaga O
    Cancer; 1997 Sep; 80(6):1034-45. PubMed ID: 9305703
    [TBL] [Abstract][Full Text] [Related]  

  • 10. [Prognostic and therapeutic significance of steroid receptors in invasive breast cancer].
    Wyss P; Rageth JC; Unger C; Hochuli E
    Geburtshilfe Frauenheilkd; 1992 Oct; 52(10):611-6. PubMed ID: 1294437
    [TBL] [Abstract][Full Text] [Related]  

  • 11. c-erbB-2 expression and response to adjuvant therapy in women with node-positive early breast cancer.
    Muss HB; Thor AD; Berry DA; Kute T; Liu ET; Koerner F; Cirrincione CT; Budman DR; Wood WC; Barcos M
    N Engl J Med; 1994 May; 330(18):1260-6. PubMed ID: 7908410
    [TBL] [Abstract][Full Text] [Related]  

  • 12. Node negative breast carcinoma: hyperprolactinemia and/or overexpression of p53 as an independent predictor of poor prognosis compared to newer and established prognosticators.
    Patel DD; Bhatavdekar JM; Chikhlikar PR; Ghosh N; Suthar TP; Shah NG; Mehta RH; Balar DB
    J Surg Oncol; 1996 Jun; 62(2):86-92. PubMed ID: 8649046
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Prognostic value of p53 and urokinase-type plasminogen activator in node-negative human breast cancers.
    Peyrat JP; Vanlemmens L; Fournier J; Huet G; Révillion F; Bonneterre J
    Clin Cancer Res; 1998 Jan; 4(1):189-96. PubMed ID: 9516970
    [TBL] [Abstract][Full Text] [Related]  

  • 14. Early experiences of breast-conservation treatment combined with tamoxifen and CAF chemotherapy for breast cancer of stages I and II.
    Ogawa Y; Nishioka A; Inomata T; Hamada N; Terashima M; Yoshida S; Tanaka Y; Ogoshi S; Araki K; Kumon M
    Radiat Med; 1994; 12(1):29-35. PubMed ID: 8016401
    [TBL] [Abstract][Full Text] [Related]  

  • 15. Tumor angiogenesis predicts clinical outcome of node-positive breast cancer patients treated with adjuvant hormone therapy or chemotherapy.
    Gasparini G; Barbareschi M; Boracchi P; Verderio P; Caffo O; Meli S; Dalla Palma P; Marubini E; Bevilacqua P
    Cancer J Sci Am; 1995; 1(2):131-41. PubMed ID: 9166466
    [TBL] [Abstract][Full Text] [Related]  

  • 16. Prognostic factors for recurrent breast cancer: univariate and multivariate analyses including histologic grade and amplification of the c-erbB-2 proto-oncogene.
    Tsuda H; Tsugane S; Fukutomi T; Nanasawa T; Yamamoto H; Hirohashi S
    Jpn J Clin Oncol; 1992 Aug; 22(4):244-9. PubMed ID: 1359174
    [TBL] [Abstract][Full Text] [Related]  

  • 17. p53 protein accumulation and response to adjuvant chemotherapy in premenopausal women with node-negative early breast cancer.
    Clahsen PC; van de Velde CJ; Duval C; Pallud C; Mandard AM; Delobelle-Deroide A; van den Broek L; Sahmoud TM; van de Vijver MJ
    J Clin Oncol; 1998 Feb; 16(2):470-9. PubMed ID: 9469330
    [TBL] [Abstract][Full Text] [Related]  

  • 18. Pilot study of primary chemotherapy with doxorubicin plus paclitaxel in women with locally advanced or operable breast cancer.
    Moliterni A; Tarenzi E; Capri G; Terenziani M; Bertuzzi A; Grasselli G; Agresti R; Piotti P; Greco M; Salvadori B; Pilotti S; Lombardi F; Valagussa P; Bonadonna G; Gianni L
    Semin Oncol; 1997 Oct; 24(5 Suppl 17):S17-10-S17-14. PubMed ID: 9374085
    [TBL] [Abstract][Full Text] [Related]  

  • 19. Prognostic variables in greek patients with stage II breast cancer: a Hellenic Cooperative Oncology Group study.
    Fountzilas G; Vasilaros S; Koukouras D; Malamos N; Pectasides D; Adamou A; Nenopoulou E; Kiriakou K; Zouvani I; Katsohis K; Kappas A; Skopa C; Semoglou C; Fahantidis E; Konstantaras C; Vasilaki E; Economopoulos T; Bacoyiannis H; Bafaloukos D; Razi E; Polichronis A; Androulakis G; Papaioannou T; Pavlidis N; Kosmidis P
    Anticancer Res; 1997; 17(6D):4681-9. PubMed ID: 9494589
    [TBL] [Abstract][Full Text] [Related]  

  • 20. HER-2 expression and response to tamoxifen in estrogen receptor-positive breast cancer: a Southwest Oncology Group Study.
    Elledge RM; Green S; Ciocca D; Pugh R; Allred DC; Clark GM; Hill J; Ravdin P; O'Sullivan J; Martino S; Osborne CK
    Clin Cancer Res; 1998 Jan; 4(1):7-12. PubMed ID: 9516946
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 64.